Novartis
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Novartis sits in the top decile of US sponsors by registered trial count (#126 of 15,742 sponsors by registered trial count).
Novartis: 265 sponsored US clinical trials, none currently recruiting.
Novartis sponsors 265 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 248 completed. 176 of these trials are in Phase 3-4 (later-stage) and 69 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 11 trials.
Top-decile sponsor footprint
Novartis ranks in the top decile of sponsors by registered trial count (#126 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
248 of 264 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
265 total, page 4 of 6
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
NCT00267202
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
NCT00280540
A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure
NCT00294086
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
NCT00277472
Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension
NCT00273299
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
NCT00260923
Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
NCT00237237
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
NCT00219193
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
NCT00251004
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
NCT00237250
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
NCT00250562
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
NCT00518765
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
NCT00138632
Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
NCT00125346
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
NCT00134966
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
NCT00130364
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
NCT00130351
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
NCT00098046
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
NCT00171405
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
NCT00141063
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
NCT00219102
Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
NCT00120536
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
NCT00219180
Fluvastatin in Adults With Dislipidemia With History of Muscle Problems
NCT00125125
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
NCT00171522
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
NCT00145327
Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
NCT00171665
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
NCT00141050
"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure
NCT00219011
Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
NCT00121381
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
NCT00127270
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
NCT00171184
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
NCT00312130
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.
NCT00171470
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
NCT00171769
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.
NCT00171457
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
NCT00294710
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
NCT00170768
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
NCT00132652
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
NCT00219076
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
NCT00228059
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes
NCT00138567
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
NCT00138606
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
NCT00219115
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
NCT00139594
To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
NCT00145275
A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
NCT00219089
Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis
NCT00154219
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B
NCT00115245
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 46 |
| Phase 3 | 126 |
| Phase 4 | 50 |
Therapeutic Areas
How the Novartis archive is shaped
265 indexed studies, none listed as recruiting (0% open); 248 completed (94%).
Phase mix: 176 late (III/IV) vs 69 early (I/II) (later-stage heavy).
Top condition: Hypertension (11 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Novartis: archived-pipeline peers nationwide
Peers matched on 265 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Novartis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 265 archived trials
- Abbott Medical Devices · 261 trials · 9% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
- Pennington Biomedical Research Center · 258 trials · 13% recruiting
- University of Texas at Austin · 257 trials · 23% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Novartis page
265 registered trials is a research-attention snapshot, not an endorsement of Novartis or any single study.
- None of Novartis's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypertension is the condition Novartis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Novartis pipeline card: 265 registered trials from official public datasets.Report a data error.